Iqvia (IQV) Stock
Global clinical research leader powering drug development. Here's the price, business snapshot, and what's worth knowing about Iqvia in November 2026.
IQVIA Holdings Inc. (IQV) is a global provider of clinical research services, real-world data, and analytics to the life sciences industry. It operates as a contract research organisation (CRO) delivering clinical trial management, regulatory support and commercial analytics, combining operational trial capabilities with large proprietary healthcare datasets and technology platforms. The business benefits from structural trends: pharmaceutical and biotech firms outsourcing R&D, rising demand for real-world evidence and use of analytics/AI to shorten time-to-market. With a market capitalisation around $37.2bn, IQVIA’s scale and global footprint are competitive advantages, though growth depends on contract wins, regulatory trends and continued tech investment. Key risks include competitive pressure, project concentration, regulatory and data-privacy challenges, and sensitivity to R&D budgets. This summary is for general educational purposes only and not personal investment advice; values can fall as well as rise and investors should check current filings and suitability for their circumstances.
Why It’s Moving
IQVIA’s Clinical Bookings Surge Signals Strong Demand for Drug Development Services
- Net new clinical bookings hit $3.2 billion in Q3, reflecting intense activity in drug trial management.
- Trailing twelve-month net new bookings grew 14% to $11.7 billion, indicating sustained pipeline strength.
- Long-term investors are focusing on these booking trends as a leading indicator of future revenue stability.
IQVIA’s Clinical Bookings Surge Signals Strong Demand for Drug Development Services
- Net new clinical bookings hit $3.2 billion in Q3, reflecting intense activity in drug trial management.
- Trailing twelve-month net new bookings grew 14% to $11.7 billion, indicating sustained pipeline strength.
- Long-term investors are focusing on these booking trends as a leading indicator of future revenue stability.
Sixth Month Growth Performance
When is the next earnings date for IQVIA HOLDINGS INC (IQV)?
No confirmed upcoming earnings date has been announced for IQVIA Holdings as of November 9, 2026. Based on the company's historical reporting pattern, which typically occurs approximately three months after the previous quarter's release, the next report is expected in February 2027. This anticipated release will cover the fourth quarter and full-year results for fiscal year 2026. Investors should monitor official corporate communications for the precise scheduling confirmation.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying IQVIA's stock, with a target price indicating potential for growth.
Financial Health
IQVIA is showing strong revenue and cash flow, indicating solid financial performance overall.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Research Demand
Outsourcing of drug development supports recurring project flow and long contract cycles, though revenues can vary with client R&D budgets and competitive pressures.
Global Footprint
A wide international presence helps win multinational trials and diversify revenues, but exposes the company to regulatory and currency headwinds.
Data and Analytics
Proprietary datasets and analytics platforms are differentiators as life sciences firms seek real‑world evidence and AI‑driven insights, though data governance is an ongoing risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
